Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4960647 | 0.77 | MET (0.42) | PARP1MAPTBRD4 | |
| SCHEMBL4960062 | 0.73 | MET (0.39) | PARP1MAPTBRD4 | |
| SCHEMBL17453369 | 0.70 | ACHE (0.46) | KDM4EALDH1A1GAAMAPTPTGS2 | |
| SCHEMBL13460967 | 0.69 | ALDH1A1 (0.50) | PARP1KDM4EALDH1A1GAA | |
| SCHEMBL17453389 | 0.68 | CHUK (0.41) | KDM4EALDH1A1GAAMAPTPTGS2 | |
| SCHEMBL4962608 | 0.67 | ALK (0.37) | — | |
| SCHEMBL5447092 | 0.66 | ALK (0.53) | — | |
| SCHEMBL11848869 | 0.64 | HTR6 (0.44) | KDM4EALDH1A1GAAMAPTHTR6 | |
| SCHEMBL16749658 | 0.63 | SMN1; SMN2 (0.46) | KDM4EALDH1A1GAAMAPTPKM | |
| SCHEMBL17453375 | 0.62 | KIF11 (0.54) | MAPTRXFP1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004684-A1 | Alpha-Carbolines as CDK-1 inhibitors | CDKL1, CDK1, CCNA1 | PARP1 123/4885KDM4E 521/4885ALDH1A1 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.